Table 4.
Overall survival curve adjustment to dacarbazine reference: HR and adjustment factor for all patients (stage IIIB–IV M1c)
Trial (drug, patient population) | HR for comparators | HR for dacarbazine | Adjustment factor |
---|---|---|---|
OPTiM (GM-CSF, previously treated and untreated) [11] | 0.22 | 0.32 | 1.46 |
MDX010-20 (gp100, previously treated) [7] | 0.34 | 0.32 | 0.95 |
GM-CSF granulocyte-macrophage colony-stimulating factor, gp100 glycoprotein 100, HR hazard ratio